Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Related Articles by Review for PubMed (Select 21419116)

1.

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.

Nagorsen D, Baeuerle PA.

Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16. Review.

PMID:
21419116
2.

Blinatumomab: a historical perspective.

Nagorsen D, Kufer P, Baeuerle PA, Bargou R.

Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Review.

PMID:
22940266
3.

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G.

Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Review.

PMID:
19455460
4.

Targeting T cells to tumor cells using bispecific antibodies.

Frankel SR, Baeuerle PA.

Curr Opin Chem Biol. 2013 Jun;17(3):385-92. doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25. Review.

PMID:
23623807
5.

Bispecific T-cell engaging antibodies for cancer therapy.

Baeuerle PA, Reinhardt C.

Cancer Res. 2009 Jun 15;69(12):4941-4. doi: 10.1158/0008-5472.CAN-09-0547. Epub 2009 Jun 9. Review.

6.

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.

Haagen IA.

Leuk Lymphoma. 1995 Nov;19(5-6):381-93. Review.

PMID:
8590837
7.

Bispecific antibodies for polyclonal T-cell engagement.

Baeuerle PA, Kufer P, Lutterbüse R.

Curr Opin Mol Ther. 2003 Aug;5(4):413-9. Review.

PMID:
14513685
8.

Bispecific monoclonal antibody therapy of B-cell malignancy.

Weiner GJ, De Gast GC.

Leuk Lymphoma. 1995 Jan;16(3-4):199-207. Review.

PMID:
7719227
9.

Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies.

Zugmaier G, Klinger M, Schmidt M, Subklewe M.

Mol Immunol. 2015 Apr 13. pii: S0161-5890(15)00088-7. doi: 10.1016/j.molimm.2015.02.033. [Epub ahead of print] Review.

PMID:
25883042
10.

CD19 as an attractive target for antibody-based therapy.

Hammer O.

MAbs. 2012 Sep-Oct;4(5):571-7. doi: 10.4161/mabs.21338. Epub 2012 Jul 23. Review.

11.

BiTEs: bispecific antibody constructs with unique anti-tumor activity.

Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA.

Drug Discov Today. 2005 Sep 15;10(18):1237-44. Review.

PMID:
16213416
12.

Advances in bispecific biotherapeutics for the treatment of cancer.

May C, Sapra P, Gerber HP.

Biochem Pharmacol. 2012 Nov 1;84(9):1105-12. doi: 10.1016/j.bcp.2012.07.011. Epub 2012 Jul 25. Review.

PMID:
22858161
13.

BiTE: Teaching antibodies to engage T-cells for cancer therapy.

Baeuerle PA, Kufer P, Bargou R.

Curr Opin Mol Ther. 2009 Feb;11(1):22-30. Review.

PMID:
19169956
14.

Targeting T cells with bispecific antibodies for cancer therapy.

Lum LG, Thakur A.

BioDrugs. 2011 Dec 1;25(6):365-79. doi: 10.2165/11595950-000000000-00000. Review.

15.

Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.

Riethmüller G.

Cancer Immun. 2012;12:12. Epub 2012 May 1. Review. No abstract available.

16.

Tumor and T cell engagement by BiTE.

Wickramasinghe D.

Discov Med. 2013 Oct;16(88):149-52. Review.

17.
18.

Antibody therapy for pediatric leukemia.

Vedi A, Ziegler DS.

Front Oncol. 2014 Apr 21;4:82. doi: 10.3389/fonc.2014.00082. eCollection 2014. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk